Related Experiment Video

Updated: Apr 17, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K

Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH)

Sandro Muntoni1, Livia Pisciotta2, Sergio Muntoni3

  • 1Oncology and Molecular Pathology Unit, Department of Biomedical Sciences, University of Cagliari, Italy; Centre for Metabolic Diseases and Atherosclerosis, The ME.DI.CO. Association, Cagliari, Italy.

Journal of Clinical Lipidology
|February 12, 2015
PubMed

Insights

This study shows that a combination of rosuvastatin and ezetimibe effectively lowered LDL cholesterol in a patient with autosomal recessive hypercholesterolemia (ARH). This treatment achieved significant lipid improvements without requiring plasmapheresis.

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Autosomal recessive hypercholesterolemia (ARH) patients exhibit distinct lipid profiles and potentially better drug responses compared to familial hypercholesterolemia homozygotes.
  • ARH, caused by LDLRAP1 gene mutations, is characterized by lower LDL-C and higher HDL-C levels.
  • The study aimed to evaluate combined drug therapy in an ARH patient, excluding plasmapheresis.

Observation:

  • A single ARH patient homozygous for the LDLRAP1 c.432insA mutation was treated with rosuvastatin (60 mg/day) and ezetimibe (10 mg/day).
  • The treatment duration was six months.
  • Genetic analysis revealed variations in PCSK9 and NPC1L1 genes in this patient.

Findings:

  • The combined treatment resulted in an 80% reduction in low-density lipoprotein cholesterol (LDL-C).
  • Significant increases in high-density lipoprotein cholesterol (HDL-C) and Apolipoprotein A-I (ApoA-I) were observed.
  • The observed lipid improvements suggest a potential synergistic effect of the drugs and possible contributions from patient-specific genetic variations.

Implications:

  • This case suggests that potent statins combined with ezetimibe can effectively manage LDL-C levels in ARH patients.
  • Achieving therapeutic goals may be possible without resorting to extracorporeal procedures like plasmapheresis.
  • Further research is warranted to confirm these findings in a larger ARH patient cohort.
Abstract

Keywords:
Autosomal recessive hypercholesterolemiaEzetimibeNPC1L1 genePCSK9 geneRosuvastatin

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K
Cholesterol Efflux Assay07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

31.0K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
613
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.1K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
879
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K